Shots:

• The collaboration supports the development of vaccines leveraging Heat’s gp96 platform designed to target SARS-CoV-2 coronavirus causing COVID-19
• Heat’s subsidiary Zolovax will focus on the development of COVID-19 vaccines while the University of Miami will develop and test vaccines utilizing Heat's gp-96 backbone- expressing antigens associated with COVID-19
• Heat's gp96-based therapeutic platform reprograms live cells to continually secrete antigens of interest bound to the gp96- thus activating a robust T-cell response against antigens

Click here ­to­ read full press release/ article | Ref: Heat Biologics | Image:  Insider Financials